Keyword: Ocrevus

A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.

Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.

Biogen's Spinraza sales only increased modestly quarter-over-quarter, but there's still plenty of growth ahead, execs say.

Crowding in the MS field hasn’t stopped Roche's Ocrevus from making a splash. But that competition has made it tough to snag reimbursement in England.

The biosimilar sales threat is getting real for Roche this year, but a lower tax rate means profits will grow just the same.

Roche managed 6% growth in the third quarter, but performance from key cancer meds highlighted biosimilar erosion ahead.

Reps. Elijah Cummings and Peter Welch announced a new probe into multiple sclerosis drug costs, digging into price hikes from seven pharmas.

Roche's highly touted new multiple sclerosis drug Ocrevus surprised the market by generating $200 million in its first quarter on the market.

A top official at Express Scripts said he’s seeing increased cooperation on pricing from the pharma industry.